These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31145100)

  • 1. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.
    Winters BR; De Sarkar N; Arora S; Bolouri H; Jana S; Vakar-Lopez F; Cheng HH; Schweizer MT; Yu EY; Grivas P; Lee JK; Kollath L; Holt SK; McFerrin L; Ha G; Nelson PS; Montgomery RB; Wright JL; Lam HM; Hsieh AC
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31145100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
    Nishiyama N; Kita Y; Ito K; Kato M; Hatakeyama S; Matsushita Y; Naito S; Miyake M; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Nishiyama H; Kobayashi T; Kitamura H;
    Anticancer Res; 2023 Nov; 43(11):5041-5050. PubMed ID: 37909969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
    Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
    Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
    Esagian SM; Khaki AR; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Santos VS; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt ME; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Msaouel P; Koshkin VS; Grivas P
    BJU Int; 2021 Aug; 128(2):196-205. PubMed ID: 33556233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
    Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
    Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
    Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
    Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.
    Audenet F; Isharwal S; Cha EK; Donoghue MTA; Drill EN; Ostrovnaya I; Pietzak EJ; Sfakianos JP; Bagrodia A; Murugan P; Dalbagni G; Donahue TF; Rosenberg JE; Bajorin DF; Arcila ME; Hechtman JF; Berger MF; Taylor BS; Al-Ahmadie H; Iyer G; Bochner BH; Coleman JA; Solit DB
    Clin Cancer Res; 2019 Feb; 25(3):967-976. PubMed ID: 30352907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy.
    Ahn B; Kim D; Park KJ; Park JM; Yoon SY; Hong B; Cho YM; Kim D
    Cancer Res Treat; 2024 Jul; 56(3):856-870. PubMed ID: 38147818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
    Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
    Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.
    Ohara K; Rendeiro AF; Bhinder B; Eng KW; Ravichandran H; Nguyen D; Pisapia D; Vosoughi A; Fernandez E; Shohdy KS; Manohar J; Beg S; Wilkes D; Robinson BD; Khani F; Bareja R; Tagawa ST; Ouseph MM; Sboner A; Elemento O; Faltas BM; Mosquera JM
    Nat Commun; 2024 Mar; 15(1):2009. PubMed ID: 38499531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
    Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
    Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
    [No Abstract]   [Full Text] [Related]  

  • 13. Genomics in upper tract urothelial carcinoma.
    Kammerer-Jacquet SF; Mathieu R; Peyronnet B; Rioux-Leclercq N; Bensalah K
    Curr Opin Urol; 2017 Jan; 27(1):35-40. PubMed ID: 27584028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study.
    Heers H; DE Geeter P; Goebell PJ; Matz U; DE Schultz W; Edlich B; Retz M; Hegele A
    Anticancer Res; 2017 Nov; 37(11):6437-6442. PubMed ID: 29061830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Adjuvant Chemotherapy for Upper Tract versus Lower Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Jazayeri SB; Liu JS; Weissman B; Lester J; Samadi DB; Feuerstein MA
    Curr Urol; 2019 Jul; 12(4):177-187. PubMed ID: 31602183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in genomic profile of high-grade urothelial carcinoma according to tumor location.
    Park CK; Cho NH
    Urol Oncol; 2022 Mar; 40(3):109.e1-109.e9. PubMed ID: 34663543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial bladder cancer.
    Xie J; Zhang XB; Wen J; Zhang YS; Li HZ
    Int Urol Nephrol; 2016 Apr; 48(4):481-7. PubMed ID: 26797856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Carcinogenic pathways and natural history of upper tract urothelial carcinomas: state-of-the-art review for the yearly scientific report of the French National Association of Urology].
    Seisen T; Cancel-Tassin G; Colin P; Cussenot O; Rouprêt M
    Prog Urol; 2014 Nov; 24(15):943-53. PubMed ID: 25158326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
    Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
    Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.